The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial.

@article{Sjamsoedin1981TheEO,
  title={The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial.},
  author={L J Sjamsoedin and Leo Heijnen and Evelien P Mauser-Bunschoten and J L van Geijlswijk and Hans JC van Houwelingen and P H van Asten and Jan J. Sixma},
  journal={The New England journal of medicine},
  year={1981},
  volume={305 13},
  pages={717-21}
}
We designed a double-blind trial to study the effect of an "activated" prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in hemophiliacs with antibodies to factor VIII. Fifteen patients received either FEIBA or the control preparation (a nonactivated prothrombin-complex concentrate) for a total of 150 bleeding episodes (four mucocutaneous bleeding, 117 joint bleeding, and 29 muscle bleeding). In 64 per cent of the episodes, FEIBA was judged by the physician to be effective… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

Acquired hemophilia a: retrospective analysis of 49 cases from a single Chinese hemophilia center.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis • 2015

Experience on using prothrombin complex concentrate in urgent warfarin reversal: an Iranian survey.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis • 2013

FVIIa as therapeutic agent in hemophilia and beyond.

Frontiers in bioscience • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…